Nov 19, 2025 04:26PM NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Nov 18, 2025 04:44PM NervGen raises US$10 million to support Nasdaq listing and drug development

Nov 18, 2025 04:42PM NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Aug 26, 2025 07:30AM NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Aug 21, 2025 07:30AM NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Jul 17, 2025 07:30AM NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Jul 7, 2025 05:30PM NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Jul 3, 2025 04:41PM NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Jul 1, 2025 07:30AM NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones

Jun 18, 2025 07:30AM NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

May 21, 2025 07:30AM NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

May 16, 2025 04:30PM NervGen Pharma Grants Stock Options

May 15, 2025 07:30AM NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

May 7, 2025 07:30AM NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Apr 21, 2025 07:30AM NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2025 05:53PM NervGen Provides Quarterly "At-The-Market" Equity Program Update

Apr 3, 2025 07:30AM NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Mar 31, 2025 07:30AM NervGen Initiates Expanded Access Policy

Mar 14, 2025 07:27PM NervGen Pharma Grants Stock Options

Mar 5, 2025 08:30AM NervGen Pharma to Present at the Virtual Life Science Investor Forum

Feb 18, 2025 04:30PM NervGen Pharma Grants Stock Options

Feb 6, 2025 07:30AM NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Jan 29, 2025 05:00PM NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025 07:30AM NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Dec 20, 2024 07:30AM NervGen Announces "At-The-Market" Equity Program

Nov 14, 2024 08:30AM NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Nov 7, 2024 08:30AM NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Sep 30, 2024 08:30AM NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Sep 20, 2024 08:30AM NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Sep 16, 2024 08:30AM NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Aug 27, 2024 08:30AM NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 22, 2024 08:30AM NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Aug 6, 2024 08:30AM NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 2, 2024 04:14PM NervGen Pharma Grants Stock Options

Jul 22, 2024 08:30AM NervGen Pharma Appoints Neil Klompas to Board of Directors

Jun 25, 2024 08:30AM NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

Jun 20, 2024 08:30AM NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium